Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: A single-center analysis

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 6, 2013, Pages 934-939

  Le Bourgeois, Amandine ^a   Mohr, Catherine ^a   Guillaume, Thierry ^a   Delaunay, Jacques ^a   Malard, Florent ^a   Loirat, Marion ^a   Peterlin, Pierre ^a   Blin, Nicolas ^a   Dubruille, Viviane ^a   Mahe, Beatrice ^a   Gastinne, Thomas ^a   Le Gouill, Steven ^a   Moreau, Philippe ^a   Mohty, Mohamad ^a,b   Planche, Lucie ^a   Lode, Laurence ^a   Bene, Marie Christine ^a   Chevallier, Patrice ^a,b  

^a HÔTEL DIEU   (France)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

Adult; Allogeneic stem cell transplantation; Cord blood; Peripheral blood stem cell; Reduced intensity conditioning regimen

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE BIPHENOTYPIC LEUKEMIA; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RADIOTHERAPY; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; DEATH; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEALTH CARE QUALITY; HEMATOLOGIC DISEASE; HEMATOLOGICAL PARAMETERS; HUMAN; LYMPHATIC SYSTEM DISEASE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; OVERALL SURVIVAL; PLATELET RECOVERY; REDUCED INTENSITY CONDITIONING; RELAPSE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UMBILICAL CORD BLOOD;

ADULT; AGED; ANTILYMPHOCYTE SERUM; BUSULFAN; CORD BLOOD STEM CELL TRANSPLANTATION; CYCLOPHOSPHAMIDE; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE;

EID: 84877880570     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.03.009     Document Type: Article

References (46)

1. Passweg J.R., Baldomero H., Gratwohl A., et al. The EBMT activity survey: 1990-2012. Bone Marrow Transplant 2012, 47:906-923.
2. Blaise D., Castagna L. Do different conditioning regimens really make a difference?. Hematology Am Soc Hematol Educ Program 2012, 2012:246-250.
3. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
4. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998, 91:756-763.
5. Michallet M., Le Q., Mohty M., et al. Predictive factors for outcomes after reduced-intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Exp Hematol 2008, 5:535-544.
6. Cahu X., Mohty M., Faucher C., et al. Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens. Bone Marrow Transplant 2008, 42:689-691.
7. Blaise D., Tabrizi R., Boher J.M., et al. Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation. Cancer 2012, 119:602-611.
8. Crocchiolo R., Esterni B., Castagna L., et al. Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases. Cancer 2012, 119:896-992.
9. Lioure B., Bene M.C., Pigneux A., et al. Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. Blood 2012, 119:2943-2948.
10. Gluckman E., Broxmeyer H.A., Auerbach A.D., et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical cord blood from an HLA-identical sibling. N Engl J Med 1989, 321:1174-1178.
11. Laughlin M.J., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004, 351:2265-2275.
12. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004, 351:2276-2285.
13. Shen B.J., Hou H.S., Zhang H.Q., et al. Unrelated, HLA-mismatched multiple human umbilical cord blood transfusion in four cases with advanced solid tumors: initial studies. Blood Cells 1994, 20:285-292.
14. Weinreb S., Delgado J.C., Clavijo O.P., et al. Transplantation of unrelated cord blood cells. Bone Marrow Transplant 1998, 22:193-196.
15. Barker J.N., Weisdorf D.J., Wagner J.E. Creation of a double chimera after the transplantation of umbilical-cord blood from two partially matched unrelated donors. N Engl J Med 2001, 344:1870-1871.
16. De Lima M., St John L.S., Wieder E.D., et al. Double-chimerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units. Br J Hematol 1992, 119:773-776.
17. Sideri A., Neokleous N., Brunet de la Grange P., et al. An overview of the progress on double umbilical cord blood transplantation. Haematologica 2011, 96:1213-1220.
18. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 2003, 102:1915-1919.
19. Brunstein C.G., Barker J.N., Weisdorf D.J., et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007, 110:3064-3070.
20. Brunstein C.G., Eapen M., Woo Ahn K., et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood 2012, 119:5591-5598.
21. Majhail N.S., Brunstein C.G., Shanley R., et al. Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is feasible option for patients without HLA-matched sibling donors. Bone Marrow Transplant 2012, 47:494-498.
22. Majhail N.S., Weisdorf D.J., Wagner J.E., et al. Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood 2006, 107:3804-3807.
23. Majhail N.S., Brunstein C.G., Tomblyn M., et al. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant 2008, 14:282-289.
24. Chen Y.B., Aldridge J., Kim H.T., et al. Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. Biol Blood Marrow Transplant 2012, 18:805-812.
25. Le Bourgeois A., Lestang E., Guillaume T., et al. Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 reimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT). Eur J Haematol 2013, 90:177-186.
26. Mohty M., de Lavallade H., Faucher C., et al. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004, 6:527-530.
27. Brissot E., Chevallier P., Guillaume T., et al. Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors. Bone Marrow Transplant 2009, 4:786-788.
28. Schichman S.A., Suess P., Vertino A.M., et al. Comparison of short tandem repeat and variable number tandem repeat genetic markers for quantitative determination of allogeneic bone marrow transplant engraftment. Bone Marrow Transplant 2002, 29:243-248.
29. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
30. Gooley T.A., Leisenring W., Crowley J., et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
31. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974, 18:295-304.
32. Shulman H., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
33. Rocha V., Rio B., Garnier F., et al. Reduced-intensity conditioning regimen in single unrelated cord blood transplantation in adults with haematological malignant disorders: a Eurocord-Netcord and SFGM-TC survey [abstract]. Blood 2006, 108:897a.
34. Rio B., Chevret S., Vigouroux S., et al. Reduced-intensity conditioning regimen prior to unrelated cord blood transplantation in patients with acute myeloid leukemia: preliminary analysis of a prospective Phase II multicentric trial on behalf of Societe Francaise de Greffe de Moelle Osseuse et Therapie Cellulaire (SFGM-TC) and Eurocord. Blood (ASH Annual Meeting Abstracts) 2010, 116. Abstracts 911.
35. Brunstein C.G., Weisdorf D.J., DeFor T., et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006, 108:2874-2880.
36. Mohty M., Gaugler B. Advances in umbilical cord transplantation: the role of thymoglobulin/ATG in cord blood transplantation. Best Pract Res Clin Haematol 2010, 23:275-282.
37. Cutler C., Stevenson K., Kim H.T., et al. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant 2011, 46:659-667.
38. Verneris M.R., Brunstein C.G., Barker J., et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009, 114:4293-4299.
39. Rocha V., Labopin M., Mohty M., et al. Outcomes after double unit unrelated cord blood transplantation (UCBT) compared with single UCBT in adults with acute leukemia in remission. a Eurocord and ALWP collaboration study [abstract]. Blood 2010, 116:910a.
40. Rodrigues C.A., Sanz G., Brunstein C.G., et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2009, 27:256-263.
41. Szabolcs P. The immunobiology of cord blood transplantation. Korean J Hematol 2010, 45:224-235.
42. Van Rood J.J., Scaradavou A., Stevens C.E. Indirect evidence that maternal microchimerism in cord blood mediates a graft-versus-leukemia effect in cord blood transplantation. Proc Natl Acad Sci USA 2012, 109:2509-2514.
43. Labopin M., Ruggeri A., Taright N., et al. Cost-effectiveness of double-unit cord blood transplantation versus single-unit cord blood transplantation in adult patients with acute leukaemia in France. Bone Marrow Transplant 2011, 47(Suppl 1):S15. [abstract].
44. Scaradavou A., Brunstein C.G., Eapen M., et al. Double-unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood 2012, 121:752-758.
45. Barker J.N., Byam C., Scaradavou A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood 2011, 117:2332-2339.
46. Cutler C., Ballen K.K. Improving outcomes in umbilical cord blood transplantation: state of the art. Blood Rev 2012, 26:241-246.